Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other neoplasm 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Endoscopy 2Cyclophosphamide 2Carboplatin 2sintilimab 1sargramostim 1fludarabine phosphate 1alethine 1Radiotherapy 1Polymerase Chain Reaction 1Papanicolaou Test 1Mycophenolic Acid 1Methylation 1Mass Spectrometry 1Immunohistochemistry 1High-Throughput Screening Assays 1Genetic Linkage 1Gene Expression Profiling 1FANG vaccine 1Erlotinib Hydrochloride 1Endoscopy, Digestive System 1Endoscopic Mucosal Resection 1Deoxyribonuclease (Pyrimidine Dimer) 1Cyclosporine 1Comparative Genomic Hybridization 1Cidofovir 1Busulfan 1Brachytherapy 1Biopsy 1Antilymphocyte Serum 1Amifostine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Precancerous Conditions × alethine × Clear all
NCT00006466 2013-12-18

Beta Alethine in Treating Patients With Myeloma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡